PFE (NYSE) - Pfizer Inc
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7170811035
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Web URL:
Classification
Market Cap in USD | 202,012m |
Sector | Healthcare |
Industry | Drug Manufacturers-General |
GiC SubIndustry | Pharmaceuticals |
TER | 0.00% |
IPO / Inception | 2012-08-13 |
Ratings
Fundamental | 3.40 |
Dividend | 6.95 |
Performance 5y | -0.06 |
Rel. Performance vs Sector | -2.18 |
Analysts | 3.65 |
Fair Price Total Ret. | 29.46 |
Fair Price DCF | todo |
Technical
Growth TTM | -22.17% |
CAGR 5y | -0.93% |
CAGR / Mean Drawdown 5y | -0.06 |
Sharpe Ratio TTM | -1.28 |
Alpha vs SP500 TTM | -35.15 |
Beta vs SP500 5y weekly | 0.67 |
CAPM | 6.81% |
Average Daily Range 2m | 1.91% |
Reversal Oscillator | 24.18 |
Volatility GJR Garch 1y | 21.95% |
Price / SMA 50 | -6.86% |
Price / SMA 200 | -16.86% |
Current Volume | 19182.7k |
Average Volume 20d | 25606.4k |
Dividends
Yield TTM | 4.94% |
Yield on Cost 5y | 4.72% |
Dividends CAGR 5y | 4.43% |
Consistency of Dividends all time | 98.4% |